← Back to Search

Virus Therapy

RiMO-401 with Radiation for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by Coordination Pharmaceuticals, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 45 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing the use of RiMO-401 with radiation in patients with advanced tumors. The study will use a specific dose of RiMO-401 injected directly into the tumor to determine the best

Who is the study for?
This trial is for adults with advanced or metastatic cancer that can't be cured by standard treatments. They should have a tumor suitable for injection and radiation, not previously treated in the last six months. Participants need to be relatively healthy (ECOG score 0-1), have recovered from past cancer therapies, expect to live at least 12 weeks, and have good organ function.
What is being tested?
The study tests RiMO-401 combined with radiation on patients with advanced tumors. It's a single-arm trial where everyone gets the same treatment. The dose of RiMO-401 is increased step-by-step in groups of patients to find the safest and most effective level.
What are the potential side effects?
Potential side effects are not explicitly listed but may include typical reactions related to intratumoral injections such as pain, swelling, infection risk at the injection site, and general side effects from radiation like fatigue, skin irritation, or nausea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~45 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 45 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determination of Recommended Dose
Secondary study objectives
Evaluation of Objective Response Rate (ORR)
Evaluation of Safety and Tolerability
Other study objectives
Evaluation of Area Under the Curve (AUC)
Evaluation of Maximum Plasma Concentration (Cmax)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: RiMO-401Experimental Treatment1 Intervention
• Single intratumoral injection followed by radiation

Find a Location

Who is running the clinical trial?

Coordination Pharmaceuticals, Inc.Lead Sponsor
5 Previous Clinical Trials
104 Total Patients Enrolled
~14 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top